Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals

 
• By Alaric DeArment

Merck’s Keytruda may nevertheless have the stronger market position given its broader and stronger labeling in second-line endometrial cancer and strong position in women’s oncology overall.

Merck presented data from a Phase III trial of Keytruda in endometrial cancer • Source: Shutterstock

More from Strategy

More from Business